Shire bets big on rare diseases

On January 19, 2016, In Director Articles, Tags ,,,
Speciality pharma firm Shire has agreed to buy Baxalta for around $32 billion (£22 billion), to further expand its portfolio of treatments for rare diseases. Baxalta, the spun-off pharmaceutical arm of Baxter, initially rejected Shire’s advances in mid-2015, saying the newly-formed company needed time to decide on its strategy. Shire gets 45% of its revenue…